- Home
- LPX vs BPMC Comparison
LPX vs BPMC Comparison
Compare LPX & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPX
- BPMC
- Stock Information
- Founded
- LPX 1973
- BPMC 2008
- Country
- LPX United States
- BPMC United States
- Employees
- LPX N/A
- BPMC N/A
- Industry
- LPX Forest Products
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- LPX Basic Materials
- BPMC Health Care
- Exchange
- LPX Nasdaq
- BPMC Nasdaq
- Market Cap
- LPX 6.1B
- BPMC 5.8B
- IPO Year
- LPX N/A
- BPMC 2015
- Fundamental
- Price
- LPX $90.65
- BPMC $97.17
- Analyst Decision
- LPX Buy
- BPMC Buy
- Analyst Count
- LPX 9
- BPMC 21
- Target Price
- LPX $108.13
- BPMC $124.05
- AVG Volume (30 Days)
- LPX 632.4K
- BPMC 973.2K
- Earning Date
- LPX 05-06-2025
- BPMC 05-01-2025
- Dividend Yield
- LPX 1.24%
- BPMC N/A
- EPS Growth
- LPX 56.47
- BPMC N/A
- EPS
- LPX 5.71
- BPMC N/A
- Revenue
- LPX $2,941,000,000.00
- BPMC $562,121,000.00
- Revenue This Year
- LPX $2.96
- BPMC $44.85
- Revenue Next Year
- LPX $6.77
- BPMC $32.06
- P/E Ratio
- LPX $15.85
- BPMC N/A
- Revenue Growth
- LPX 8.09
- BPMC 99.19
- 52 Week Low
- LPX $78.82
- BPMC $73.04
- 52 Week High
- LPX $122.87
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- LPX 56.65
- BPMC 59.54
- Support Level
- LPX $86.12
- BPMC $87.03
- Resistance Level
- LPX $92.99
- BPMC $104.86
- Average True Range (ATR)
- LPX 2.73
- BPMC 3.86
- MACD
- LPX 0.94
- BPMC 1.24
- Stochastic Oscillator
- LPX 77.46
- BPMC 64.38
About LPX Louisiana-Pacific Corporation
Louisiana-Pacific is primarily an oriented strand board producer and also offers engineered wood siding used in home construction and repair and remodel projects. The company is largely exposed to the North American housing market but has also established capacity in Brazil and Chile.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.